Patents Assigned to X-Ceptor Therapeutics, Inc.
-
Publication number: 20100056582Abstract: Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: ApplicationFiled: December 17, 2008Publication date: March 4, 2010Applicant: X-CEPTOR THERAPEUTICS, INC.Inventors: Christopher D. Bayne, Alan T. Johnson, Shao-Po Lu, Raju Mohan, Michael C. Nyman, Edwin J. Schweiger, William C. Stevens, JR., Haixia Wang, Yinong Xie
-
Patent number: 7482366Abstract: Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: GrantFiled: July 24, 2004Date of Patent: January 27, 2009Assignee: X-Ceptor Therapeutics, Inc.Inventors: Christopher D Bayne, Alan T Johnson, Shao-Po Lu, Raju Mohan, Michael C Nyman, Edwin J Schweiger, William C Stevens, Jr., Haixia Wang, Yinong Xie
-
Publication number: 20080070864Abstract: Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.Type: ApplicationFiled: March 4, 2003Publication date: March 20, 2008Applicant: X-Ceptor Therapeutics, Inc.Inventors: Richard Martin, Jeffrey D. Kahl, Brenton T. Flatt, Ronald Griffith
-
Publication number: 20070293464Abstract: Novel compositions and methods of using substituted pyrimidines which have the general formula: (I)Type: ApplicationFiled: November 9, 2004Publication date: December 20, 2007Applicant: X-Ceptor Therapeutics, Inc.Inventors: Richard Martin, Raju Mohan, Peter Ordentlich
-
Publication number: 20070225377Abstract: The present invention is directed to 1?,25-dihydroxyvitamin D3 mimics which modulate the vitamin D receptor (VDR). The invention is further directed to pharmaceutical compositions and methods for the treatment, prevention or amelioration of one or more symptoms of disease or disorder related to the activity of the vitamin D receptor using an effective amount of a compound of formula (I).Type: ApplicationFiled: October 13, 2004Publication date: September 27, 2007Applicant: X-Ceptor Therapeutics, Inc.Inventors: Brenton Flatt, Richard Martin, Raju Mohan, Brett Murphy
-
Publication number: 20070015746Abstract: Compounds, compositions and methods are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder related to the activity of the receptors.Type: ApplicationFiled: July 23, 2004Publication date: January 18, 2007Applicant: X-CEPTOR THERAPEUTICS INC.Inventors: Richard Martin, Tie-Lin Wang, Brenton Flatt, Xiao-Hui Gu
-
Patent number: 7115640Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.Type: GrantFiled: November 18, 2003Date of Patent: October 3, 2006Assignee: X-Ceptor Therapeutics, Inc.Inventors: Richard Martin, Brenton T Flatt, Jeffrey D Kahl, Tie-Lin Wang
-
Patent number: 6924311Abstract: The present invention relates to methods for elevating high density lipoprotein (HDL) plasma levels, decreasing the absorption of dietary cholesterol in the intestine, decreasing the plasma level of low density lipoprotein (LDL), and increasing the conversion of cholesterol to bile acids, utilizing LXR? selective agonists, usually without elevating the plasma levels of triglycerides. Also provided are methods of using such agonists to treat metabolic diseases alone or in combination with other active agents. Also provided are methods for decreasing hyperglycemia and insulin resistance methods for treating type II diabetes, and methods for treating type II diabetes and reducing the cardiovascular complications of type II diabetes, utilizing an LXR agonist. Further provided are methods for treating obesity and methods for treating the complications of obesity including type II diabetes, cardiovascular disease, hyperlipidemia, and hypertension, administering an LXR?-selective antagonist.Type: GrantFiled: October 17, 2001Date of Patent: August 2, 2005Assignee: X-Ceptor Therapeutics, Inc.Inventors: Ira G. Schulman, Eric D. Bischoff, Rajendra K. Tangirala
-
Publication number: 20050080111Abstract: Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: ApplicationFiled: July 24, 2004Publication date: April 14, 2005Applicant: X-Ceptor Therapeutics, Inc.Inventors: Christopher Bayne, Alan Johnson, Shao-Po Lu, Raju Mohan, Michael Nyman, Edwin Schweiger, William Stevens, Haixia Wang, Yinong Xie
-
Publication number: 20040204447Abstract: Compounds of formula (I): 1Type: ApplicationFiled: December 17, 2003Publication date: October 14, 2004Applicants: X-Ceptor Therapeutics Inc., Sankyo Company, LimitedInventors: Alan T. Johnson, Satoru Kaneko, Raju Mohan, Kozo Oda, Edwin J. Schweiger
-
Publication number: 20040180942Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.Type: ApplicationFiled: November 18, 2003Publication date: September 16, 2004Applicant: X-Ceptor Therapeutics, Inc.Inventors: Richard Martin, Brenton Todd Flatt, Jeffrey Dean Kahl, Tie-Lin Wang
-
Patent number: 6696473Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.Type: GrantFiled: December 20, 2002Date of Patent: February 24, 2004Assignee: X-Ceptor Therapeutics, Inc.Inventors: Richard Martin, Brenton Todd Flatt, Jeffrey Dean Kahl, Tie-Lin Wang
-
Publication number: 20040023947Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.Type: ApplicationFiled: May 27, 2003Publication date: February 5, 2004Applicant: X-Ceptor Therapeutics Inc.Inventors: Richard Martin, Tie-Lin Wang, Brenton T. Flatt, Xiao-Hui Gu, Ronald Griffith